等待開盤 02-05 09:30:00 美东时间
+0.205
+5.26%
LAUSANNE, Switzerland, Feb. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today anno...
02-03 05:05
Issued on behalf of Oncolytics Biotech Inc. Equity-Insider.com News Commentary VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The oncology sector is undergoing a massive capital rotation driv...
01-30 23:36
ADC Therapeutics SA (ADCT) said on Thursday it expects preliminary unaudited net product revenue of about $22 million for the fourth quarter of 2025 and approximately $73 million for the full year. Th...
01-09 05:25
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today provided corporate updates and highlights from its ZYNLONTA® clinical program.
01-09 05:16
LAUSANNE, Switzerland, Jan. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today anno...
01-03 05:05
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has...
2025-12-19 20:55
U.S. stock futures were mixed this morning, with the Dow futures gaining around...
2025-12-04 21:00
Zynlonta and glofitamab show high response and durable remission rates in early r/r DLBCL trial data from ADC Therapeutics, with enrollment ongoing into 2026.
2025-12-04 03:40
Company to host corporate webcast to share updated data on December 3, 2025 LAUSANNE, Switzerland, Dec. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global le...
2025-12-03 05:05
LAUSANNE, Switzerland, Dec. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today anno...
2025-12-02 05:05